On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.